JP2018502924A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018502924A5 JP2018502924A5 JP2017556780A JP2017556780A JP2018502924A5 JP 2018502924 A5 JP2018502924 A5 JP 2018502924A5 JP 2017556780 A JP2017556780 A JP 2017556780A JP 2017556780 A JP2017556780 A JP 2017556780A JP 2018502924 A5 JP2018502924 A5 JP 2018502924A5
- Authority
- JP
- Japan
- Prior art keywords
- baclofen
- dose
- solution
- administration
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 claims description 64
- 229960000794 baclofen Drugs 0.000 claims description 64
- 238000001990 intravenous administration Methods 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 30
- 239000000243 solution Substances 0.000 claims description 26
- 208000006011 Stroke Diseases 0.000 claims description 10
- 238000007913 intrathecal administration Methods 0.000 claims description 10
- 238000001802 infusion Methods 0.000 claims description 9
- 206010012735 Diarrhoea Diseases 0.000 claims description 5
- 206010025476 Malabsorption Diseases 0.000 claims description 5
- 208000004155 Malabsorption Syndromes Diseases 0.000 claims description 5
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 claims description 5
- 206010047700 Vomiting Diseases 0.000 claims description 5
- 230000002496 gastric effect Effects 0.000 claims description 5
- 208000008384 ileus Diseases 0.000 claims description 5
- 208000014674 injury Diseases 0.000 claims description 5
- 208000003243 intestinal obstruction Diseases 0.000 claims description 5
- 238000001356 surgical procedure Methods 0.000 claims description 5
- 230000008733 trauma Effects 0.000 claims description 5
- 230000008673 vomiting Effects 0.000 claims description 5
- 239000003186 pharmaceutical solution Substances 0.000 claims description 4
- 239000000812 cholinergic antagonist Substances 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 230000001773 anti-convulsant effect Effects 0.000 claims description 2
- 230000002921 anti-spasmodic effect Effects 0.000 claims description 2
- 239000001961 anticonvulsive agent Substances 0.000 claims description 2
- 229960003965 antiepileptics Drugs 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 claims description 2
- 239000008121 dextrose Substances 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 7
- 229940124597 therapeutic agent Drugs 0.000 claims 7
- 210000003462 vein Anatomy 0.000 claims 2
- 230000001078 anti-cholinergic effect Effects 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562103902P | 2015-01-15 | 2015-01-15 | |
| US62/103,902 | 2015-01-15 | ||
| PCT/US2016/013672 WO2016115504A1 (en) | 2015-01-15 | 2016-01-15 | Intravenous baclofen formulations and treatment methods |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018502924A JP2018502924A (ja) | 2018-02-01 |
| JP2018502924A5 true JP2018502924A5 (enExample) | 2019-02-28 |
Family
ID=56406482
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017556780A Pending JP2018502924A (ja) | 2015-01-15 | 2016-01-15 | 静脈内バクロフェン製剤および治療方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (5) | US10350183B2 (enExample) |
| EP (1) | EP3244884A4 (enExample) |
| JP (1) | JP2018502924A (enExample) |
| CA (1) | CA2974091A1 (enExample) |
| MX (1) | MX2017009313A (enExample) |
| WO (1) | WO2016115504A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10350183B2 (en) | 2015-01-15 | 2019-07-16 | Allaysis, Llc | Intravenous baclofen formulations and treatment methods |
| MX2018004656A (es) * | 2015-10-21 | 2019-01-10 | Allaysis Llc | Baclofeno intravenoso y metodos de tratamiento. |
| US20230190570A1 (en) * | 2020-06-22 | 2023-06-22 | Otivio As | Methods for treating spasticity using anti-spasmodic compositions and negative pressure therapy |
| EP4019016A1 (en) * | 2020-12-24 | 2022-06-29 | Allaysis, LLC | Methods of administering intravenous baclofen |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH26730A (en) | 1988-12-30 | 1992-09-28 | Ciba Geigy Ag | Coated adhesive tablets |
| EP0461958B1 (fr) | 1990-06-15 | 1994-09-14 | Synthelabo | Dérivés de 2-(aminoalkyl)-5-(arylalkyl)-1,3-dioxanes, leur préparation et leur application en thérapeutique |
| IT1319275B1 (it) * | 1999-10-08 | 2003-09-26 | Neuroscienze S C A R L | Uso del baclofen nel trattamento dell'astinenza da etanolo. |
| US6969383B2 (en) | 2002-09-27 | 2005-11-29 | Medtronic, Inc. | Method for treating severe tinnitus |
| WO2005037215A2 (en) * | 2003-10-14 | 2005-04-28 | Massachusetts Institute Of Technology | Compositions and methods for enhancing cognitive function and synaptic plasticity |
| US7824697B2 (en) * | 2004-07-12 | 2010-11-02 | Board Of Regents, The University Of Texas System | High concentration baclofen preparations |
| RS55585B1 (sr) * | 2006-11-22 | 2017-06-30 | Clinical Research Associates LLC | Postupci za lečenje daunovog sindroma, krhkog x sindroma i autizma |
| US9180108B2 (en) * | 2011-10-27 | 2015-11-10 | Medtronic, Inc. | Baclofen formulations and methods for making same |
| US9622997B2 (en) * | 2012-06-01 | 2017-04-18 | Lynn Health Science Institute, Inc. | Methods for treating insomnia |
| US10350183B2 (en) | 2015-01-15 | 2019-07-16 | Allaysis, Llc | Intravenous baclofen formulations and treatment methods |
-
2016
- 2016-01-15 US US14/997,135 patent/US10350183B2/en active Active
- 2016-01-15 MX MX2017009313A patent/MX2017009313A/es unknown
- 2016-01-15 CA CA2974091A patent/CA2974091A1/en not_active Abandoned
- 2016-01-15 EP EP16737994.0A patent/EP3244884A4/en not_active Withdrawn
- 2016-01-15 WO PCT/US2016/013672 patent/WO2016115504A1/en not_active Ceased
- 2016-01-15 JP JP2017556780A patent/JP2018502924A/ja active Pending
-
2019
- 2019-07-01 US US16/459,004 patent/US20200038353A1/en not_active Abandoned
- 2019-07-01 US US16/458,994 patent/US10933042B2/en active Active
-
2021
- 2021-02-01 US US17/164,366 patent/US20210228520A1/en not_active Abandoned
-
2023
- 2023-04-19 US US18/136,777 patent/US12295929B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Raskin | Lumbar puncture headache: a review | |
| Buck et al. | Use of dexmedetomidine in the pediatric intensive care unit | |
| Tulman et al. | Advances in management of acute hypertension: a concise review | |
| RU2012117563A (ru) | Режим дозирования модулятора рецептора s1p | |
| JP2018502924A5 (enExample) | ||
| RU2015134581A (ru) | Доноры нитроксила с улучшенным терапевтическим индексом | |
| JP2020172520A (ja) | 腹水の治療 | |
| JP2017519799A5 (enExample) | ||
| JP2017501154A5 (enExample) | ||
| JP2018531605A5 (enExample) | ||
| CN114728012A (zh) | 用于治疗癫痫持续状态的加奈索酮 | |
| CN102149377A (zh) | 决奈达隆在制备用于预防中风或短暂性缺血发作的药物中的用途 | |
| Gottlieb | Bolus dose of epinephrine for refractory post-arrest hypotension | |
| JP2014511365A5 (enExample) | ||
| JP2018502924A (ja) | 静脈内バクロフェン製剤および治療方法 | |
| Fraticelli et al. | A novel iloprost administration method with portable syringe pump for the treatment of acral ulcers and Raynaud’s phenomenon in systemic sclerosis patients. A pilot study (ILOPORTA) | |
| KR20120138229A (ko) | 정맥내 투여용 이부프로펜을 이용한 중증 환자의 치료 | |
| JP2020535139A (ja) | シポニモドの投与レジメン | |
| KR20170118830A (ko) | 조현병의 치료를 위한 일로페리돈 | |
| CN108815171B (zh) | 25-羟基胆固醇在制备治疗或预防心肌梗死的药物中的应用 | |
| JP2005516050A (ja) | 急性心筋梗塞のための複合治療 | |
| Adams et al. | Evaluation and pharmacologic approach to patients with resistant hypertension | |
| Mentz et al. | Blood pressure, safety and clinical efficacy of vericiguat in chronic heart failure with reduced ejection fraction: Insights from the VICTOR trial | |
| JP6420923B1 (ja) | 医薬 | |
| Ozaslan et al. | Hyoscine-N-butylbromide induced ventricular tachycardia during ERCP |